http://orcid.org/0000-0001-8790-4675
References
- Pleyer C, Sun C, Desai, et al. Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. Leuk Lymphoma. 2020;61(10):2375–2382.
- Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–1127.
- Waller EK, Miklos D, Cutler C, et al. Ibrutinib for chronic graft-versus-host-disease after failure of prior therapy: 1-year update of a phase 1b/2 study. Biol Blood Marrow Tr. 2019;25(10):2002–2007.
- Rogers KA, Mousa L, Zhao Q, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. 2019;33(10):2527–2530.
- Munir T, Brown JR, O'Brien S, et al. Final analysis from resonate: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.
- Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506.
- Khurana D, Arneson LN, Schoon RA, et al. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol. 2007;178(6):3575–3582.
- Herman SEM, Montraveta A, Niemann CU, et al. The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831–2841.
- Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–2219.
- Reda G, Cassin R, Gentile M, et al. IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. Leukemia. 2019;33(6):1519–1522.
- Ishdorj G, Streu E, Lambert P, et al. IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv. 2019;3(14):2188–2198.
- Bercusson A, Colley T, Shah A, et al. Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132(18):1985–1988.
- Bechman K, Galloway JB, Winthrop KL. Small-molecule protein kinase inhibitors and the risk of fungal infections. Curr Fungal Infect Rep. 2019;13(4):229–243.
- Zou Y-X, Zhu H-Y, Li X-T, et al. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Hematol Oncol. 2019;37(4):392–400.
- Flinsenberg TWH, Tromedjo CC, Hu N, et al. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica. 2020;105(2):e76–e79.
- Carrington EM, Zhan Y, Brady JL, et al. Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitor and in vivo. Cell Death Differ. 2017;24(5):878–910.
- Khaw SL, Merino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival BCL-2 with ABT-199. Leukemia. 2014;28(6):1207–1215.
- de Weerdt I, Hofland T, de Boer R, et al. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv. 2019;3(17):2642–2652.
- Svanberg R, Ostrowski SR, Bay JT, et al. Combined Ibrutinib and Venetoclax changes myeloid phenotype and improves immune function in CLL patients. Blood. 2019;134(Supplement_1):4289–4289.
- Davis J, Handunnetti SM, Sharpe C, et al. Long term responses to venetoclax and ibrutinib in mantle cell lymphoma are associated with immunological recovery and prognostic changes in inflammatory biomarkers. Blood. 2019;134(Supplement_1):2791–2791.